GLP-1 medications, including subcutaneous injections and tablets, have been a hot trend, followed by this new GLP-1 patch social media phenomenon
This strategy works particularly well for established patients who know their optimal dose and are committed to long-term treatment
It established two cohorts: 244,063 patients in the GLP-1 RA treatment group (Victoza, Saxenda, Ozempic, Wegovy) and 11,439,560 patients in the non-GLP-1 RA group
Anti-Inflammatory Properties: Reduces inflammation, contributing to better overall wellness
This whole market is going to be changing so much in the coming months, said Tracey Phillips, chief pharmacy officer at virtual health care provider Felix Health